

OCT 15 2002

PATENT &amp; TRADEMARK OFFICE

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10-31-02 OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

PTO SB 21-08

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

7

Application Number 09/928,047

Filing Date 10 August 2001

First Named Inventor Tom L. CANTOR

Group Art Unit 1614

Examiner Name To be assigned

Attorney Docket No. 532212000200

**ENCLOSURES (check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Reply☐ After Final☐ Affidavits/declarations☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement;  
form 1449; 2 references☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/  
Incomplete Application☐ Response to Missing Parts  
under 37 CFR 1.52 or 1.53☐ Assignment Papers  
(for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s):☐ After Allowance Communication to  
Group☐ Appeal Communication to Board of  
Appeals and Interferences☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please identify  
below)

Return postcard

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm

or

Individual Name

Signature

Date

Peng Chen  
Registration No. 43,543

October 7, 2002

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 7, 2002.

Susan B. Lynch

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

sd-97867



PATENT  
Docket No. 532212000200

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on October 14, 2002.

Susan B. Lynch

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Thomas L. CANTOR

Serial No.: 09/928,047

Filing Date: August 10, 2001

For: CYCLASE INHIBITING  
PARATHYROID HORMONE  
ANTAGONISTS OR MODULATORS  
AND OSTEOPOROSIS

Examiner: To be assigned

Group Art Unit: 1614

RECEIVED  
OCT 17 2002  
TECH CENTER 600 2900

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the document numbers 15 and 53 are submitted herewith. Copies of the remaining references were submitted in an Information Disclosure Statement, directed to related Application Numbers 10 002,818, filed November 2, 2001, and 09-231,422, filed January 14, 1999. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: October 9, 2002

By: \_\_\_\_\_

Peng Chen  
Registration No. 43,543

Morrison & Foerster LLP  
3811 Valley Centre Drive,  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5117  
Facsimile: (858) 720-5125

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Docket Number 532212000200

Application Number 09/928,047


Applicant

Thomas I. CANTOR

Filing Date August 10, 2001

Group Art Unit 164

Mailing Date October 1, 2002



RECEIVED  
OCT 15 2002  
TECHNICAL UNIT 164

## U.S. PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date    | Document No. | Name               | Class | Subclass | Filing Date If Appropriate |
|-------------------|----------|---------|--------------|--------------------|-------|----------|----------------------------|
|                   | 1        |         | 09/231,422   |                    |       |          | January 14, 1999           |
|                   | 2        |         | 09/344,639   |                    |       |          | June 26, 1999              |
|                   | 3        |         | 09/928,047   |                    |       |          | August 10, 2001            |
|                   | 4        |         | 09/636,530   |                    |       |          | August 10, 2001            |
|                   | 5        |         | 09/636,531   |                    |       |          | August 10, 2000            |
|                   | 6        |         | 10/002,818   |                    |       |          | November 2, 2001           |
|                   | 7        |         | 60/224,396   |                    |       |          | August 10, 2000            |
|                   | 8        |         | 09/928,048   |                    |       |          | August 10, 2001            |
|                   | 9        |         | 09/323,606   |                    |       |          | June 2, 1999               |
|                   | 10       | 01/1983 | 4,369,138    | Lindall            | 260   | 112.5    |                            |
|                   | 11       | 12/1983 | 4,423,037    | Rosenblatt et al.  | 424   | 177      |                            |
|                   | 12       | 04/1985 | 4,508,828    | Lindall et al.     | 436   | 500      |                            |
|                   | 13       | 04/1987 | 4,656,250    | Morita et al.      | 530   | 324      |                            |
|                   | 14       | 02/2000 | 6,030,790    | Adermann et al.    | 435   | 7.1      |                            |
|                   | 15       | 04/2000 | 6,051,686    | Krstenansky et al. | 530   | 333      |                            |


## FOREIGN PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date    | Document No. | Country | Class | Subclass | Translation YES NO |
|-------------------|----------|---------|--------------|---------|-------|----------|--------------------|
|                   | 16       | 07/1985 | DE 33 47 548 | Germany |       |          |                    |
|                   | 17       | 04/1996 | DE 44 34 551 | Germany |       |          |                    |
|                   | 18       | 12/2001 | EP 0 783 522 | Europe  |       |          |                    |
|                   | 19       | 05/1991 | WO 91 06564  | PCT     |       |          |                    |
|                   | 20       | 04/1993 | WO 93 06845  | PCT     |       |          |                    |
|                   | 21       | 02/1994 | WO 94 03201  | PCT     |       |          |                    |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

|  |                               |                              |
|--|-------------------------------|------------------------------|
| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION<br>IN AN APPLICATION<br> | Docket Number 532212000200    | Application Number 097928047 |
|  | Applicant<br>Thomas I. CANFOR |                              |
|  | Filing Date August 10, 2001   | Group Art Unit 1614          |
|  | Mailing Date October 1, 2002  |                              |

|     |         |             |     |
|-----|---------|-------------|-----|
| 22. | 04 1996 | WO 96 10041 | PCT |
|-----|---------|-------------|-----|

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

| Examiner Initials | Ref. No. | Title  |
|-------------------|----------|--|
|                   | 23.      | Adermann et al., in: Innovations and Perspectives in Solid Phase Synthesis, Epton (ed.), Mayflower World Wide, Birmingham (1994) pp.429-432  |
|                   | 24.      | Atkinson et al., Journal of Immunoassay (1982) 3(1):31-51  |
|                   | 25.      | Blind et al., Clin. Chem. (1987) 33(8):1376-1381   |
|                   | 26.      | Bowie et al., Science (1990) 247:1306-1310   |
|                   | 27.      | Brossard et al., Journal of Clinical Endocrinology and Metabolism (1996) 81(11):3923-3929  |
|                   | 28.      | Campbell, Monoclonal Antibody and Immunosensor Technology, in Laboratory Techniques in Biochemistry and Molecular Biology, van der Vliet (ed.), Elsevier (1991) pp.1-11, 42-45   |
|                   | 29.      | Caporale and Rosenblatt, Parathyroid Hormone Antagonists Effective in vivo, in: Advances in Experimental Medicine and Biology, New York (1986) pp. 315-327   |
|                   | 30.      | Clinical Chemistry (1999) 45(6)Suppl:A97 b, Abstract Nos. 339-341  |
|                   | 31.      | D'Amour et al., Am. J. Physiol. (1986) 251:E680-E687   |
|                   | 32.      | Daniel et al., Virology (1994) 202:540-549   |
|                   | 33.      | Divieti, P. et al. (2001). <i>J Bone Miner Res</i> 2001:Suppl 1, S307.   |
|                   | 34.      | Faugere, M.C. et al. (2001). <i>Kidney International</i> 60:1460-1468.   |
|                   | 35.      | Faugere, M.C. et al. <i>Nephrology, Bone &amp; Mineral Metabolism</i> A3995.   |
|                   | 36.      | Fischer et al., The Journal of Clinical Investigation (1974) 54:1382-1394  |
|                   | 37.      | Gao et al., Clinica Chimica Acta (1996) 245:39-59  |
|                   | 38.      | Goodman, W. et al. (2000). <i>NEJM</i> 342:20, 1478-1483.  |
|                   | 39.      | Gordon et al., Parathyroid Hormone Domain for Protein Kinase C Stimulation Located within Amphiphilic Helix, in: Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium, June 16-21, 1991, Cambridge, MA, Smith and Rivier (eds.) Escom Science Publishers (1992) pp.37-39 |
|                   | 40.      | Hashimoto et al., Journal of Cardiovascular Pharmacology (1981) 3(4):668-676   |
|                   | 41.      | Hehrmann et al., Journal of Immunoassay (1980) 1(2):151-174  |
|                   | 42.      | John et al., Journal of Clinical Endocrinology and Metabolism (1999) 84(11):4287-4290  |
|                   | 43.      | LePage et al., Clin. Chem. (1998) 44:805-810   |

RECEIVED  
 OCT 1 1999  
 TECH CENTER 3600

|  |                  |
|--|------------------|
| EXAMINER:  | DATE CONSIDERED: |
| EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. |                  |

Form PTO-1449

Docket Number 532212000200

Application Number 09/928,047

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Applicant

Thomas L. CANTOR

Filing Date August 10, 2001

Group Art Unit 1614

Mailing Date October 1, 2002



- |    |   |
|----|---|
| 44 | Logue et al., Journal of Immunological Methods (1991) 137:159-166   |
| 45 | Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(1):197-204   |
| 46 | Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(II):783-787  |
| 47 | Mallette, Journal of Clinical Endocrinology and Metabolism (1980) 50(1):201-203   |
| 48 | Nakamura et al., Endocrinol. JPN (1981) 28(4):547-549   |
| 49 | Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., (eds.), Birkhäuser Boston (1994) pp.492-495   |
| 50 | Niall et al., Proc. Natl. Acad. Sci. USA (1974) 71(2):384-388   |
| 51 | Nussbaum et al., Chemical Abstracts (1982) 96(5):181-192  |
| 52 | Pang et al., Pharmacol. Exp. Ther. (1981) 216(3):567-571  |
| 53 | Podbesek et al. (1983), Endocrinology 112(3):1000-1006  |
| 54 | Qi et al., Am. J. Kidney Dis. (1995) 26:622-631   |
| 55 | Quarles et al., J. Clin. Endocrinol. Metab. (1992) 75:145-150   |
| 56 | Stadler, Homologous Radioimmunoassay for Human Parathyroid Hormone (Residues 1-34) with Biotinylated Peptide as Tracer, in Calcium Regulating Hormones, Vitamin D Metabolites, and Cyclic AMP Assays and their Clinical Application, Schmidt-Gayk et al., (eds.), Berlin/Heidelberg, Springer, (1990) pp. 137-150 |
| 57 | Tampe et al., J. Immunoassay (1992) 13(1):1-13  |
| 58 | Visser et al., Acta Endocrinology (1979) 90:90-102  |
| 59 | Wingender et al., Structure-Function Relationship in Parathyroid Hormone in: Advances in Protein Design, International Workshop, Blöcker et al. (eds.), VCH (1988) pp.167-176   |
| 60 | Zanelli et al., Journal of Immunoassay (1983) 4(2):175-206  |
| 61 | Zemplar package insert, Abbott Reference (1998), 06-9998-R1-Rev. Roche Laboratories.  |

RECEIVED

TECH. CENTER 1600 2900

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.